Erratum: Development of the "inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo (Clinical Pharmacology and Therapeutics (2007) 82 (532-540) doi:10.1038/sj.clpt.6100187);Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 5, 2007, Pages 531-540

  Ryu, J Y ^a   Song, I S ^a   Sunwoo, Y E ^a   Shon, J H ^a,b   Liu, K H ^a   Cha, I J ^a   Shin, J G ^a,b  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 5 HYDROXYOMEPRAZOLE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DEXTRORPHAN; KAFESOFT; LOSARTAN POTASSIUM; MIDAZOLAM; OMEPRAZOLE; OMEPRAZOLE DERIVATIVE; PARAXANTHINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG URINE LEVEL; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; IN VIVO STUDY; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; URINALYSIS; VALIDATION STUDY;

EID: 35448974964     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.105     Document Type: Erratum

References (48)

1. Rendic, S. & Di Carlo, F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev 29, 413-458 (1997).
2. Nebert, D.W. & Russell, D.W. Clinical importance of the cytochromes P450. Lancet 360, 1155-1162 (2002).
3. Guengerich, F.P. Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am. J. Clin. Nutr. 61(Suppl): 651S-658S (1995).
4. Bertilsson, L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet. 29, 192-209 (1995).
5. Wormhoudt, L.W., Commandeur, J.N.M. & Vermeulen, N.P.A. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit. Rev. Toxicol. 29, 59-124 (1999).
6. Van der Weide, J. & Steijns, L.S. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann. Clin. Biochem. 36, 722-729 (1999).
7. Frye, R.F., Matzke, G.R., Adedoyin, A., Porter, J.A. & Branch, R.A. Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug metabolizing enzymes. Clin. Pharmacol. Ther. 62, 365-376 (1997).
8. Streetman, D.S., Bertino, J.S. & Nafziger, A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10, 187-216 (2000).
9. Streetman, D.S. et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin. Pharmacol. Ther. 68, 375-383 (2000).
10. Zhu, B. et al. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin. Pharmacol. Ther. 70, 455-461 (2001).
11. Christensen, M. et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin. Pharmacol. Ther. 73, 517-528 (2003).
12. Chainuvati, S. et al. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2D6 and 3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown 5+1 cocktail". Clin. Pharmacol. Ther. 74, 437-447 (2003).
13. Tanaka, E., Kurata, N. & Yasuhara, H. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J. Clin. Pharm. Ther. 28, 157-165 (2003).
14. Onrot, J. et al. Reduction of liver plasma flow by caffeine and theophylline. Clin. Pharmacol. Ther. 40, 506-510 (1986).
15. Tenneze, L., Verstuyft, C., Becquemont, L., Poirier, J.M., Wilkinson, G.R. & Funck-Brentano, C. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. Clin. Pharmacol. Ther. 66, 582-588 (1999).
16. Paolini, M., Biagi, G.L., Bauer, C. & Cantelli-Forti, G. Cocktail strategy: complications and limitations. J. Clin. Pharmacol. 33, 1011-1012 (1993).
17. Miners, J.O. & Birkett, D.J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45, 525-538 (1998).
18. Fuhr, U. et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6, 159-176 (1996).
19. Carrillo, J.A. et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther. Drug Monit. 22, 409-417 (2000).
20. Rostami-Hodjegan, A., Nurminen, S., Jackson, P.R. & Tucker, G.T. Caffeine urinary metabolite ratios as markers of enzyme activity a theoretical assessment. Pharmacogenetics 6, 121-149 (1996).
21. Spigset, O., Hagg, S., Soderstrom, E. & Dahlqvist, R. The paraxanthine caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics 9, 409-412 (1999).
22. Yasar, U. et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther. 71, 89-98 (2002).
23. Yasar, U. et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab. Dispos. 29, 1051-1056 (2001).
24. Chang, M., Dahl, M.L., Tybring, G., Gotharson, E. & Bertilsson, L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5, 358-363 (1995).
25. Roh, H.K., Dahl, M.L., Tybring, G., Yamada, H., Cha, Y.N. & Bertilsson, L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6, 547-551 (1996).
26. Wang, J., Wang, Y., Fawcett, J.P., Wang, Y. & Gu, J. Determination of omeprazole in human plasma by liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry. J. Pharm. Biomed. Anal. 39, 631-635 (2005).
27. Fuhr, U., Jetter, A. & Kirchheiner, J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "Cocktail" approach. Clin. Pharmacol. Ther. 81, 270-283 (2007).
28. Zhou, H., Tong, Z. & McLeod, J.F. "Cocktail" approaches and strategies in drug development: valuable tool or flawed science? J. Clin. Pharmacol. 44, 120-134 (2004).
29. Labbe, L. et al. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10(5): 425-438 (2000).
30. Jones, D.R., Gorski, J.C., Haehner, B.D., O'Mara, E.M. & Jr Hall, S.D. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin. Pharmacol. Ther. 60, 374-384 (1996).
31. Borges, S., Li, L., Hamman, M.A., Jones, D.R., Hall, S.D. & Gorski, JC Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab. Dispos. 33, 1052-1055 (2005).
32. Kinirons, M.T. et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin. Pharmacol. Ther. 54, 621-629 (1993).
33. Gill, H.J., Tingle, M.D. & Park, B.K. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br. J. Clin. Pharmacol 40, 531-538 (1995).
34. Kinirons, M.T. et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin. Pharmacol. Ther 66, 224-231 (1999).
35. Blakey, G.E. et al. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. Br. J. Clin. Pharmacol. 57, 162-169 (2004).
36. Gorski, J.C., Jones, D.R., Haehner-Daniels, B.D., Hamman, M.A., O'Mara, E.M. & Hall, S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64, 133-143 (1998).
37. Lee, J.I., Chaves-Gnecco, D., Amico, J.A., Kroboth, P.D., Wilson, J.W. & Frye, R.F. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin. Pharmacol. Ther. 72, 718-728 (2002).
38. Lin, Y.S. et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11, 781-791 (2001).
39. Krupka, E. et al. Probe of CY P3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers. Eur. J. Clin. Pharmacol. 62, 653-659 (2006).
40. Gorski, J.C., Jones, D.R., Haehner-Daniels, B.D., Hamman, M.A., O'Mara, E.M. & Hall, S.D. CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64, 133-143 (1998).
41. Palmer, J.L., Scott, R.J., Ginson, A., Dickins, M. & Pleasance, S. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br. J. Clin. Pharmacol. 52, 555-561 (2001).
42. Gaedigk, A., Gotschall, R.R., Forbes NS Simon, S.D., Kearns, G.L. & Leeder, J.S. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9, 669-682 (1999).
43. Schadel, M., Wu, D., Otton, S.V., Kalow, W. & Sellers, E.M. Pharmacokinetics of dextromethorphan and metabolites in humans: Influence of the CYP2D6 phenotype and quinidine inhibition. J. Clin. Psychopharmacol. 15, 263-269 (1995).
44. Gonzalez, L., Lopez, J.A., Alonso, R.M. & Jimenez, R.M. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid hromatography with fluorimetric detection. J. Chromatogr. A. 949, 49-60 (2002).
45. Yu, K.S. et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin. Pharmacol. Ther. 76, 104-112 (2004).
46. Wang, J., Wang, Y., Fawcett, J.P., Wang, Y. & Gu, J. Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux. Ther. Drug Monit. 26, 3-8 (2004).
47. Food and Drug Administration. FDA Guidance for Industry . In vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis, And Recommendations For Dosing And Labeling, FDA, Rockville, MD, (1999).
48. Lee, L.S., Bertino, J.S. Jr & Nafziger, A.N. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J. Clin. Pharmacol. 46, 229-234 (2006).